European Union-Funded Project to Result in Novel Treatment Approaches for Several Solid Tumor Types – QNT Press Release


Indivumed and CELLphenomics Announce Partnership for Improved Cancer Patient Care

BERLIN and HAMBURG, Germany, Sept. 7, 2022 /PRNewswire/ — Indivumed GmbH (“Indivumed”) and CELLphenomics GmbH (“CELLphenomics”) today announced a partnership to create a unique platform for faster and more efficient discovery and validation of therapeutic targets. The new platform combines Indivumed’s AI-driven oncology analytics with CELLphenomics’ expertise in creating organoid models to identify therapeutically relevant targets and validate these targets in-vitro. The partnership will accelerate cancer drug development by linking in-silico target discovery and development with matched patient-derived tumor models for downstream validation.

“Leveraging our multi-omics database and AI-driven oncology analytics is what allows us to decipher the complex mechanisms of cancer in order to drive the development of precision oncology,” said Prof. Dr. Hartmut JuhlCEO and Founder of Indivumed. “By partnering with CELLphenomics, we will be able to quickly validate therapeutically relevant targets to identify new treatment approaches and accelerate cancer drug development in the future.”

The partnership announcement comes after Indivumed was

Full story available on Benzinga.com



Source link

Recommended For You

About the Author: News Center